title: Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia.
abstract: The interaction between menin and oncogenic mixed lineage leukemia (MLL) fusion proteins is required for leukemic transformation and may represent a therapeutic opportunity. In this issue of Cancer Cell, Borkin and colleagues describe the development of highly potent small-molecule inhibitors of this interaction that reverse the leukemic phenotype and prolong survival in murine models of MLL-rearranged leukemia.
authors: Cancer Biology and Genetics Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
authors: Michael W M
authors: MW
authors: Kühn
authors: Cancer Biology and Genetics Program and Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: armstros@mskcc.org.
authors: Scott A
authors: SA
authors: Armstrong
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D051788:Myeloid-Lymphoid Leukemia Protein / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*
chemical_list: D011518:Proto-Oncogene Proteins; D051788:Myeloid-Lymphoid Leukemia Protein